41.8%), and ceftazidime (36%). Interestingly, 43 (30.5%) (E coli -18, K pneumonia -8, E aerogenes -8, P aeruginosa -6, Pseudomonas spp. -3) of the 141 MBL producers were sensitive to both imipenem and meropenem by the CLSI DDST, with zone sizes of 16-21 mm. Of the 338 isolates, 80 (23.7%) produced all three of the newer β-lactamases [ Table 1]. In vitro resistance to amikacin, gentamicin, and ciprofl oxacin was signifi cantly higher (P < .05) in isolates producing all three newer β-lactamases compared to the rest (68.5%, 97.3%, and 83.6% vs 50.8%, 59.8% ,and 52.5%, respectively).
References1. Gupta V. An update on newer beta-lactamases. Indian J Med Res 2007;126:417-27. 2. Performance Standards for Antimicrobial Susceptibility Testing; 17th informational supplement, Clinical and Laboratory Standards Institute (CLSI) M100-S17: Vol. 27, 17 th ed. Clinical and Laboratory Standards Institute, Wayne, PA; 2007. p. 3. 3. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005;18:657-86. 4. Black JA, Thomson KS, Buynak JD, Pitout JD. Evaluation of β-lactamase inhibitors in disk tests for detection of plasmidmediated AmpC β-lactamases in well-characterized clinical strains of Klebsiella spp. J Clin Microbiol 2005;43:4168-71. 5. Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-β-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol 2008;26:233-7. 6. Marchiaro P, Mussi MA, Ballerini V, Pasteran F, Viale AM, Vila AJ, et al, Sensitive EDTA-based microbiological assays for detection of metallo-{beta}-lactamases in nonfermentative gram-negative bacteria. J Clin Microbiol 2005;43:5648-52.